12805EA8192OpenA Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to NephroureterectomyThis phase III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery may enhance the shrinking of the tumor compared to chemotherapy alone.
NCT04628767NationalAdultTreatment
Drug: Cisplatin
Drug: Doxorubicin Hydrochloride
Biological: Durvalumab
Drug: Gemcitabine Hydrochloride
Drug: Methotrexate
Biological: Pegfilgrastim
Procedure: Therapeutic Conventional Surgery
Drug: Vinblastine SulfateIIIGlobalKidneyThis study identifies the following disease or condition: Renal Pelvis and Ureter Urothelial Carcinoma
Rapisuwon, SutheeMedStar Health and GUMC; Medstar Washington Hospital CenterGenito-urinaryOncology GroupMHRI Washington Cancer Institute; NCA MU NCORP 2021R3.1 Build 22 <a href="https://advarra.com" target="_blank">© 2024 Advarra, Inc.</a>